 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 20, 2016 |
| Title |
CCL19 as a Chemokine Risk Factor for Posttreatment Lyme Disease |
| Platform organism |
synthetic construct |
| Sample organism |
Homo sapiens |
| Experiment type |
Protein profiling by protein array
|
| Summary |
Approximately 10% to 20% of patients optimally treated for early Lyme disease develop persistent symptoms of unknown pathophysiology termed posttreatment Lyme disease syndrome (PTLDS). The objective of this study was to investigate associations between PTLDS and immune mediator levels during acute illness and at several time points following treatment. Seventy-six participants with physician-documented erythema migrans and 26 healthy controls with no history of Lyme disease were enrolled. Sixty-four cytokines, chemokines, and inflammatory markers were measured at each visit for a total of 6 visits over 1 year. An operationalized definition of PTLDS incorporating symptoms and functional impact was applied at 6 months and 1 year following treatment completion, and clinical outcome groups were defined as the return-to-health, symptoms-only, and PTLDS groups. Significance analysis of microarrays identified 7 of the 64 immune mediators to be differentially regulated by group. Generalized logit regressions controlling for potential confounders identified posttreatment levels of the T-cell chemokine CCL19 to be independently associated with clinical outcome group. Receiver operating characteristic analysis identified a CCL19 cutoff of >111.67 pg/ml at 1 month following treatment completion to be 82% sensitive and 83% specific for later PTLDS. We speculate that persistently elevated CCL19 levels among participants with PTLDS may reflect ongoing, immune-driven reactions at sites distal to secondary lymphoid tissue. Our findings suggest the relevance of CCL19 both during acute infection and as an immunologic risk factor for PTLDS during the posttreatment phase. Identification of a potential biomarker predictor for PTLDS provides the opportunity to better understand its pathophysiology and to develop early interventions in the context of appropriate and specific clinical information.
|
| |
|
| Overall design |
A total of 65 immune and inflammatory mediators were profiled in serum samples derived from early Lyme disease patients and age- and sex-matched controls. These samples have been generated as part of a prospective cohort study that includes a well-defined cohort of patients with acute Lyme disease enrolled from a Lyme endemic area of the mid-Atlantic United States. Only patients with untreated, confirmed early Lyme disease manifesting an active EM skin lesion at the time of enrollment, as defined by CDC case criteria are eligible. Patients with a history of prior Lyme disease or the presence of confounding preexisting medical conditions associated with prolonged fatigue, pain or neurocognitive symptoms are excluded. Controls are nonhospitalized age- and sex-matched and have no prior history of Lyme disease or any exclusionary medical conditions including lack of inflammatory disorders.
|
| |
|
| Contributor(s) |
Aucott JN, Soloski MJ, Rebman A, Crowder LA, Lahey LJ, Wagner CA, Lingampalli N, Robinson WH, Bechtold KT |
| Citation missing |
Has this study been published? Please login to update or notify GEO. |
| |
| Submission date |
Jul 15, 2016 |
| Last update date |
Jul 20, 2016 |
| Contact name |
William Robinson |
| E-mail(s) |
wrobins@stanford.edu
|
| Phone |
650-849-1207
|
| Organization name |
Stanford University
|
| Street address |
269 Campus Dr
|
| City |
Stanford |
| State/province |
CA |
| ZIP/Postal code |
94305 |
| Country |
USA |
| |
|
| Platforms (1) |
| GPL18408 |
Stanford – Robinson Lab - Cytokine and Acute Phase Assays - 65 - v1.0 |
|
| Samples (589)
|
|
| Relations |
| BioProject |
PRJNA329638 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE84479_raw_data_matrix.txt.gz |
81.9 Kb |
(ftp)(http) |
TXT |
| Processed data included within Sample table |
|
|
|
|
 |
Less...
More...